Johnson & Johnson (JNJ) said Friday that data from a phase 3 study of Tremfya subcutaneous induction therapy in adults with moderately to severely active ulcerative colitis showed "statistically significant" and "clinically meaningful" improvements compared to a placebo.
The company said the results for the drug, also called guselkumab, were consistent with the intravenous induction regimen already approved last year by the US Food and Drug Administration.
At week 12, 26.6% of patients in the study treated with a 400 milligram dose showed clinical remission compared with 6.5% for the placebo while 65.6% showed a clinical response compared with 34.5% for the placebo, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.